A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients

Inflamm Bowel Dis. 2020 Jun 18;26(7):1098-1109. doi: 10.1093/ibd/izz252.

Abstract

Background: Providing timely follow-up care for patients with inflammatory bowel disease in remission is important but often difficult because of resource limitations. Using smartphones to communicate symptoms and biomarkers is a potential alternative. We aimed to compare outpatient management using 2 smartphone apps (IBDsmart for symptoms and IBDoc for fecal calprotectin monitoring) vs standard face-to-face care. We hypothesized noninferiority of quality of life and symptoms at 12 months plus a reduction in face-to-face appointments in the smartphone app group.

Methods: Inflammatory bowel disease outpatients (previously seen more often than annually) were randomized to smartphone app or standard face-to-face care over 12 months. Quality of life and symptoms were measured quarterly for 12 months. Acceptability was measured for gastroenterologists and patients at 12 months.

Results: One hundred people (73 Crohn's disease, 49 male, average age 35 years) consented and completed baseline questionnaires (50 in each group). Intention-to-treat and per-protocol analyses revealed noninferiority of quality of life and symptom scores at 12 months. Outpatient appointment numbers were reduced in smartphone app care (P < 0.001). There was no difference in number of surgical outpatient appointments or number of disease-related hospitalizations between groups. Adherence to IBDsmart (50% perfect adherence) was slightly better than adherence to IBDoc (30% perfect adherence). Good acceptability was reported among most gastroenterologists and patients.

Conclusions: Remote symptom and fecal calprotectin monitoring is effective and acceptable. It also reduces the need for face-to-face outpatient appointments. Patients with mild-to-moderate disease who are not new diagnoses are ideal for this system.

Clinical trial registration number: ACTRN12615000342516.

Keywords: eHealth; mHealth; remote symptom monitoring.

Publication types

  • Equivalence Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aftercare / methods*
  • Ambulatory Care / statistics & numerical data
  • Feces / chemistry
  • Female
  • Gastroenterologists / statistics & numerical data
  • Humans
  • Inflammatory Bowel Diseases / therapy*
  • Intention to Treat Analysis
  • Leukocyte L1 Antigen Complex / analysis
  • Male
  • Mobile Applications*
  • Patient Acceptance of Health Care / statistics & numerical data
  • Quality of Life
  • Remission Induction
  • Smartphone
  • Surveys and Questionnaires
  • Symptom Assessment / methods*
  • Telemedicine / methods*

Substances

  • Leukocyte L1 Antigen Complex

Associated data

  • ANZCTR/ACTRN12615000342516